Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1369-1378

  Zhou, Bingsen ^a   Mi, Shu ^a   Mo, Xueli ^a   Shih, Jennifer ^a   Tsai, Jeffery ^a   Hu, Edward ^a   Hsu, Margaret ^a   Kay, Kristie ^a   Yen, Yun ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Drug resistance; Gemcitabine; Hydroxyurea; Ribonucleotide reductase; Triphosphate pools

Indexed keywords

DEOXYCYTIDINE; DEOXYCYTIDINE TRIPHOSPHATE; GEMCITABINE; HYDROXYUREA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MODEL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CYTIDINE DIPHOSPHATE; DEOXYCYTIDINE; DEOXYRIBONUCLEOTIDES; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; HYDROXYUREA; KB CELLS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

EID: 0036323457     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Experimental and clinical studies of 2′-fluoroarabinosylpyrimidines and purine-like C-nucleosides
2. Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2′2′-difluoro-D-ribofuranosyl nucleo-sides
3. Evaluation of the antitumor activity of Gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
4. Antitumor activity of 2′-deoxy-2′,2′-difluorocytidine, a novel inhibitor of ribonucleotide reductase
5. 2′2′-difluorodeoxycytidine metabolism and mechanism of action on human leukemia cells
6. Action of 2′2′-difluorodeoxycytidine on DNA synthesis
7. Comparison of the cellular pharmacokinetics and toxicity of 2′2′-difluorodeoxycytidine and 1 β-D-arabinofuranosylcytosine
8. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine
9. Preclinical in vivo activity of 2′, 2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer
10. Gemcitabine: Current status of Phase I and Phase II trials
11. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780
12. A Phase I clinical, plasma, and cellular pharmacology study of Gemcitabine
13. Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation of mononuclear cells during a phase I trial of Gemcitabine
14. Effect of patients age on Gemcitabine toxicity profile and efficacy in advanced non-small lung cancer (NSCLC)
15. Phase I dose escalation study of cisplatin in combination with Gemcitabine in non-small cell lung cancer
16. A Phase I study of Gemcitabine in combination with hydroxyurea in patients with advanced solid tumors
17. Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells
18. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers
19. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine
20. Role of the M2 subunit of ribonucloetide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2′, 3′-dideoxyinosine
21. Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hyroxyurea
22. Methods for thymidylate synthase pharmacodynamics: Serial biopsy, free and total TS, FdUMP and dUMP and H4PteGlu and CH2-H 4PteGlu assays
23. A phase II pilot trial of high-dose hydroxyurea in chronic myelogenous leukemia
24. Mechanism of action of hydroxyurea
25. 2′-deoxy-2′-methylenecytidine and 2′-deoxy-2′, 2′-difluorocytidine 5′-diphosphastes: Potent mechanism-based inhibitors of ribonucleotide reductase
26. Leukemia L 1210 cell lines resistant to ribonucleotide reductase inhibitors
27. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′, 2′-difluorodeoxycytidine
28. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues
29. Purification of deoxycytidine kinase from two P815 murine neoplasms and their separation from deoxyguanosine kinase
30. Increased sensitivity of hydroxyurea-resistant leukemic cells to Gemcitabine
31. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2 difluorodeoxycytidine in the human KB cancer cell line
32. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis
33. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea (HU) in combination with Gemcitabine (GEM): A California Cancer Consortium Trial